Equashield
EQUASHIELD is a privately held medical device company that develops Closed System Transfer Devices (CSTDs) and AI-powered automated compounding systems for safe handling of hazardous drugs, serving 3,000+ hospitals globally with 44% US CSTD market share.
- Company typePrivate
- Founded2012
- HeadquartersPort Washington, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Equashield does
EQUASHIELD is a privately held medical device company that specializes in Closed System Transfer Devices (CSTDs) and adjacent automated compounding technologies for the safe handling of hazardous drugs used in chemotherapy and other sterile clinical settings. Founded in 2004 and headquartered in Port Washington, New York, with manufacturing operations in Israel, the company serves hospital pharmacies, oncology nurses, compounding pharmacists, biopharmaceutical manufacturers, CDMOs, and veterinary professionals across more than 25 countries spanning five continents. EQUASHIELD has been named the most-used CSTD in the United States for nine consecutive years and holds approximately 44% US market share, with a customer base of more than 3,000 hospitals and a customer retention rate above 99%.
The company's core offering is a portfolio of proprietary CSTD components — closed-back syringe units (sizes from 1 mL to 60 mL), vial adaptors, spike adaptors, female connectors, luer lock adaptors, and IV tubing sets — built around an integrated barrier-type pressure equalization system and a leak-preventing dry disconnection mechanism that mechanically prevent vapor escape and microbial ingress. On top of this hardware base, the company has layered an automated compounding platform: Mundus HD for general hazardous drug compounding at up to 37 doses per hour, Mundus Neo for pediatric and neonatal precision dosing, and EQUASHIELD Pro for high-throughput compounding at up to 70 doses per hour. The Mundus systems use embedded cameras and machine vision to verify every dose three times and integrate with electronic medical records (EMR) for digital order-to-administration workflows. The company has also extended its closed-system technology via CellSHIELD into cell and gene therapy manufacturing for biopharma and CDMOs. Four US patents (US 8,196,614; US 10,398,627; US 10,765,601; US 9,610,222) protect the core syringe and adaptor technology, and regulatory clearances include FDA 510(k) under product code ONB (K221513) and CE mark under EU MDR 2017/745.
EQUASHIELD generates revenue primarily through hardware sales of CSTD components and capital equipment, supplemented by clinical training services and a compliance platform partnership with Pharmacy Stars. Distribution follows a hybrid model: a direct enterprise field sales force and clinical account managers in the United States, complemented by every major US wholesaler (ABC, Cardinal Health, McKesson, Morris & Dickson, Oncology Supply, Owens & Minor, Medline, Concordance) and regional distributors internationally; U.S. customers can also order directly through an online portal. Marketing is content-driven, anchored by the EQ Academy educational platform, peer-reviewed clinical studies, and a heavy presence at ASHP and similar industry events. In October 2022, Nordic Capital acquired a major stake with a reported $300 million investment to support expansion of AI-enabled automated compounding and global growth.
Equashield firmographics
Firmographics- Name
- Equashield
- Legal name
- EQUASHIELD LLC
- Website
- https://equashield.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- EQUASHIELD is a privately held medical device company that develops Closed System Transfer Devices (CSTDs) and AI-powered automated compounding systems for safe handling of hazardous drugs, serving 3,000+ hospitals globally with 44% US CSTD market share.
- Ownership category
- akta.pro rank
Equashield industry classification
Industry- Product category
- Medical Devices — Closed System Transfer Devices (CSTDs) for Hazardous Drug Handling
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Compounding Pharmacy & Sterile Prep Workflow Systems (HLACAKAM)
- akta.pro secondary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Equashield is headquartered
LocationHeadquarters
- HQ city
- Port Washington
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Equashield business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- CSTD Products (Syringe Units, Vial Adaptors, Spike Adaptors): Sale of closed system transfer device components including syringe units in multiple sizes (1mL to 60mL), vial adaptors (13mm to 32mm), spike adaptors, and accessories. Products sold through distributor network and direct sales.
- Automated Compounding Systems (Mundus HD, Mundus Neo): Sale of automated compounding equipment including Mundus HD and Mundus Neo systems with AI-powered image processing capabilities. Includes modular design for pharmacy workflow integration.
- Consumables and Accessories: Recurring revenue from consumable CSTD components and accessories including tubing sets, luer lock adaptors, female connectors, and protective plugs that require ongoing repurchase.
- Clinical Training and Compliance Services: Premium clinical and educational support services including on-site training, clinical consulting, quarterly visits, and ongoing support. Partnership with Pharmacy Stars for compliance platform services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard CSTD components available through wholesale distribution |
| Other | Multi-year contract | Automated compounding systems with customized purchasing plans |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
Equashield product offering
Product offeringCore offering
Equashield manufactures and sells the EQUASHIELD Closed System Transfer Device (CSTD) platform — proprietary closed-back syringes, vial adaptors, spike adaptors, female connectors, luer lock adaptors, and IV tubing sets that prevent hazardous drug vapor escape, aerosol leakage, and microbial ingress during chemotherapy compounding and administration. The company complements its manual CSTD system with AI-enabled automated pharmacy compounding equipment (Mundus HD, Mundus Neo, and EQUASHIELD Pro) using machine vision for dose verification, and the CellSHIELD device family for cell/gene therapy sterile manufacturing. Products are sold to hospital pharmacies, oncology clinics, biopharma companies, and CDMOs through direct sales, an online ordering portal, and a network of national and international distributors.
Product overview
EQUASHIELD is a global compounding technology company offering a unified product ecosystem centered on hazardous drug handling safety. The core portfolio consists of EQUASHIELD CSTD (Closed System Transfer Device) technology including closed-back syringe units, vial adaptors, spike adaptors, female connectors, luer lock adaptors, and IV tubing sets. This manual CSTD system is complemented by automated compounding solutions: Mundus HD for general hazardous drug compounding (up to 37 doses/hour), Mundus Neo for pediatric precision compounding, and EQUASHIELD Pro for high-throughput needs (up to 70 doses/hour). The CellSHIELD product line addresses cell/gene therapy sterile manufacturing. Additional offerings include EQ Academy educational resources and Pharmacy Stars compliance platform integration. All products share the common goal of protecting healthcare workers from hazardous drug exposure through closed-system technology.
Differentiator
Problem solved
Functional benefit
Brands
- CellSHIELD: IP-protected closed family of devices for cell/gene therapy manufacturing ensuring prevention of microbial contamination
- Mundus HD
- Mundus Neo
- EQUASHIELD Pro
- EQUASHIELD Pro
Products and services
- EQUASHIELD CSTD (Closed System Transfer Device) System Industry-leading closed system transfer device platform with closed-back syringe units and adaptors for hazardous drug compounding and administration. Features integrated barrier-type pressure equalization, leak-preventing dry disconnection mechanism, and encapsulated plunger rod to prevent vapor escape and contamination. Sold to hospital pharmacies, oncology clinics, and compounding facilities.
- Mundus HD Automated hazardous drug compounding solution using EQUASHIELD's proven CSTDs with automation, embedded cameras, machine vision, and AI-powered image analysis for dose verification. Delivers up to 37 individual doses per hour with full traceability, complete documentation, and EMR integration for hospital pharmacy customers.
- Mundus Neo Automated pediatric compounding system with precision-guided dosing, validated double-membrane design to prevent microbial contamination, and advanced accuracy for small doses. Designed for neonatal and pediatric hospital pharmacy customers, with complete documentation and traceability.
- EQUASHIELD Pro High-throughput automated compounding robot producing up to 70 doses per hour with the smallest footprint in the industry. Uses CSTD from start to finish for maximum safety, efficiency, and accuracy in hazardous drug compounding for hospital pharmacy customers.
- CellSHIELD IP-protected closed family of devices for cell/gene therapy sterile manufacturing that prevents microbial contamination throughout cell therapy production processes. Enables biopharma companies and CDMOs to safely scale up manufacturing operations without expensive Grade A biosafety cabinets. Targeted at biopharma manufacturers and CDMOs.
- EQUASHIELD Syringe Units (SU Series) Closed-back syringe units with integrated pressure equalization system that prevent vapor and aerosol escape. Available in sizes from 1mL to 60mL with permanently bonded connectors and shielded needles for needlestick prevention. Consumable component sold to hospital pharmacies for hazardous drug compounding.
- Vial Adaptors (VA Series) Snap-on vial adaptors providing contamination-free vial access with a microbial barrier preventing ingress for up to 10 connections in 7 days. Available in multiple sizes (13mm to 32mm) including concave variants for thick stoppers. Consumable component for hazardous drug handling.
- Spike Adaptors (SA Series) Secure IV bag connection adaptors facilitating safe transfer of hazardous drugs. Includes SA-EZ, SA-EZ/D, SA-180, SA-1J, and SA-EZM variants with internal locking mechanisms preventing accidental disconnection.
- Female Connectors (FC Series) Leak-free female luer lock connectors that convert standard ports into closed system connections. Includes FC-1 standard and FC-1S swivel variants with dual membranes preventing drug residues and enabling dry connections.
- Luer Lock Adaptors (LL Series) Secure connections to patient lines for safe injection and infusion, including LL-2, LL-2S (swivel), LL-2C (catheter), and multipack variants with enclosed lever for safe disengagement.
- IV Tubing Sets Integrated tubing sets combining spike adaptors or luer-lock adaptors with tubing for safe medication transfer to IV bags. Includes SA-EZ/E, SA-EZ/ST, SA-EZ/F (with filter for Paclitaxel), and LL-1Y Y-site tubing variants.
- SA-180 & FC-180 Set Combined spike adaptor and female luer lock connector set for efficient preparation and administration of multiple chemotherapy drugs. Reduces components needed and enables flexible multi-drug treatment workflows.
- EQUASHIELD Safety Platform Comprehensive integrated safety platform combining CSTD technology with automated compounding and IV workflow software. Offers automated safety checks and seamless workflow standardization for hospital pharmacy hazardous drug handling.
- Pharmacy Stars Compounding360 Compliance Platform Integration Cloud-based pharmacy regulatory compliance platform offered in partnership with Pharmacy Stars. Combines EQUASHIELD CSTD technology with Compounding360 software for USP, NAPRA, TJC, and 340B compliance management, SOPs, and year-round CSTD training across health systems.
Quantifiable outcome
- 44% of CSTDs in use for hazardous drug preparation in US hospitals
- +9 more outcomes
Companies that use Equashield
Customer profileNamed customers2 records
Segments7 records
Ideal customer profiles4 records
Equashield technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability7 records
Feature6 records
Equashield partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Pharmacy StarscoreStrategic partnership for pharmacy compliance solutions. Combines EQUASHIELD's CSTD technology with Pharmacy Stars' Compounding360 cloud-based compliance platform. Joint offerings include year-round CSTD training, USP 797 compliance support, and exclusive partnership discounts for new and existing customers.
- Local Recycling OrganizationsminorPartnerships with local recycling organizations to recycle approximately 40 tons of plastic manufacturing residues annually, contributing to circular economy initiatives and sustainable manufacturing practices.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Equashield competitors and assessment
Company assessmentDirect peers
- Becton Dickinson (BD): BD manufactures the BD PhaSeal Closed System Transfer Device, the original CSTD launched in the late 1990s. BD is the most direct competitor to EQUASHIELD in hospital pharmacy hazardous drug handling and operates with significantly broader portfolio and resources.
- ICU Medical: ICU Medical produces the ChemoClave CSTD system and competes head-to-head with EQUASHIELD in hazardous drug compounding. The company also offers broader IV therapy and critical care products, making it a strong direct competitor with adjacent portfolio leverage.
- B. Braun Medical: B. Braun manufactures the OnGuard CSTD system and TPN compounding equipment, directly competing with EQUASHIELD in hazardous drug and sterile compounding safety. B. Braun's large global footprint and broad hospital supplies portfolio make it a meaningful direct peer.
- Terumo Medical: Terumo manufactures closed system drug transfer devices and broader drug delivery / infusion products, including Surplug and related CSTD offerings. Terumo overlaps with EQUASHIELD's CSTD product line and shares exposure to hospital pharmacy compounding workflows.
Emerging players
- Yukon Medical: Yukon Medical is a smaller specialized CSTD competitor offering closed system transfer devices for hazardous drug handling. It is a direct niche competitor to EQUASHIELD with a narrower product portfolio and limited geographic reach.
- Corvida Medical: Corvida Medical has developed the Halo Closed System Transfer Device as a newer entrant in the CSTD category. It competes with EQUASHIELD in hazardous drug safety with technology focused on usability improvements.
Broad incumbents
- Baxter International: Baxter offers a broad hospital products portfolio including IV solutions, infusion pumps, and pharmacy compounding technologies. While not a pure-play CSTD competitor, Baxter overlaps with EQUASHIELD's hospital pharmacy and compounding workflow offerings.
- Smiths Medical: Smiths Medical manufactures specialty medical devices including infusion systems and related drug delivery products relevant to hazardous drug administration. It is comparable as a broader hospital-focused medical device peer adjacent to EQUASHIELD's compounding focus.
- Cytiva (Danaher): Cytiva, part of Danaher, provides bioprocessing and cell/gene therapy manufacturing technologies including single-use systems and sterile connectors. It is comparable to EQUASHIELD's CellSHIELD business serving cell/gene therapy manufacturing workflows at CDMOs and biopharma companies.
Others
- West Pharmaceutical Services: West Pharmaceutical Services manufactures drug containment and delivery components including stoppers, seals, and syringe components used in injectable drug packaging. It is comparable to EQUASHIELD at the component level for injectable and parenteral drug handling.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Equashield social profiles
Digital presenceEquashield compliance and trust
Trust signalCompliance2 records
Equashield financial estimates
Financial estimateRevenue estimate
Valuation estimate
Equashield leadership team
Management profileNumber of profiles
Profiles6 records
Equashield funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Equashield M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Equashield
What does Equashield do?
Equashield manufactures and sells the EQUASHIELD Closed System Transfer Device (CSTD) platform — proprietary closed-back syringes, vial adaptors, spike adaptors, female connectors, luer lock adaptors, and IV tubing sets that prevent hazardous drug vapor escape, aerosol leakage, and microbial ingress during chemotherapy compounding and administration. The company complements its manual CSTD system with AI-enabled automated pharmacy compounding equipment (Mundus HD, Mundus Neo, and EQUASHIELD Pro) using machine vision for dose verification, and the CellSHIELD device family for cell/gene therapy sterile manufacturing. Products are sold to hospital pharmacies, oncology clinics, biopharma companies, and CDMOs through direct sales, an online ordering portal, and a network of national and international distributors.
Is Equashield a public or private company?
Equashield is a private company. It is classified as private equity controlled and is currently operating.
When was Equashield founded?
Equashield was founded in 2012. It employs 251 to 500 people.
Where is Equashield based?
Equashield is headquartered in Port Washington, United States, in the North America region.
How does Equashield make money?
Four revenue lines are on record. CSTD Products (Syringe Units, Vial Adaptors, Spike Adaptors) is the primary driver. The others are automated Compounding Systems (Mundus HD, Mundus Neo), consumables and Accessories and clinical Training and Compliance Services.
Who are Equashield's main competitors?
Direct peers on record are Becton Dickinson (BD), ICU Medical, B. Braun Medical and Terumo Medical. Emerging players are Yukon Medical and Corvida Medical. Broad incumbents are Baxter International, Smiths Medical and Cytiva (Danaher). West Pharmaceutical Services is listed as an others.
Does Equashield have an API?
No public API is recorded for Equashield.
What industry is Equashield in?
Equashield's product category is Medical Devices — Closed System Transfer Devices (CSTDs) for Hazardous Drug Handling. Its primary akta.pro industry code is HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems, with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 339113 and its SIC code is 3841.